Publicerad: 2021-12-09 10:33 | Uppdaterad: 2021-12-09 11:13

Aktuella utlysningar, vecka 49, 2021

Grants Office tipsar om aktuella anslag

Svenska och nordiska anslag


Erik Allardt fellowship - Helsinki Collegium for Advanced Studies

Enables one or two scholars, within social and human sciences, with an affiliation with a university in Sweden to undertake a fellowship at the collegium in Helsinki. Fellowship includes a monthly grant of €3,600 and a travel allowance of €1,000 per semester for either the entire academic year or one semester.

Closing date: 10 January 2022

Further information 


Call for projects – SRP Diabetes Postdoc Fellowships 2022

SRP Diabetes at KI started a new initiative earlier this year – the SRP Diabetes Postdoctoral Fellowship Programme. With this postdoctoral program SRP Diabetes aims to support the next generation of exceptional young scientists within the diabetes area, including both experimental and clinical research. This call is the first step in our second round of recruitment of 5 postdoctoral fellows for an expected start date in the autumn of 2022. Principal investigators at Karolinska Institutet are hereby invited to submit a project for consideration to the SRP Diabetes Postdoctoral Fellowship Program within basic, translational, clinical, and/or epidemiological research with an emphasis on diabetes and its comorbidities (e.g. cardiovascular and liver disease). Projects should have clear relevance for diabetic disease and principal investigators should document their track record in diabetes related research. Applications will be externally evaluated.

Closing date: 16 January 2022

Further information 

Doktorandmånader – Radiumhemmets forskningsfonder

Utlysningens syfte är att möjliggöra för kliniskt verksamma doktorander inom cancerområdet att genomföra sina doktorandprojekt genom att finansiera forskningstid. Medlen utlyses som lönemedel och kan sökas från och med registrering som doktorand till disputation.

Closing date: 30 January 2022

Further information 


Project grants - Swedish Research Council for Health, Working Life and Welfare (Forte)

The annual call for project grants is open to applications within Forte’s overall areas of responsibility: health, working life and welfare. Grants are worth up to SEK 3 million for two-year projects and up to SEK 5million for three-year projects.

Closing date: 3 February 2022

Further information 


EASD/Novo Nordisk Foundation diabetes prize for excellence

Recognises a body of research that has led to significant advances in the understanding, prevention or treatment of diabetes or its complications. The prize is worth DKK 6 million.

Closing date: 15 February 2022

Further information 


Lise Meitner Grants for Israeli-Swedish research collaboration – Swedish Foundation for Strategic Research (SSF)

In a collaboration between SSF and the Israeli Ministry of Innovation, Science and Technology, MOST, it is now possible to apply for grants in the joint program “Lise Meitner Grants for Israeli-Swedish research collaboration”. An amount of 50 million SEK is invested in applied research projects involving groups in Israel and Sweden of the highest international scientific standard. The aim is to enhance the two countries’ strong position in research and innovation and to create networks, which also can spread positive effects to other actors in academia and industry. Around eight projects will be supported by research grants, which should be used for joint research, seminars, conferences, workshops and exchanges of individuals between the applying groups over a period of five years.

Closing date: 21 February 2022

Further information 

Europeiska anslag


CERV-2022-EQUAL – call for proposals to promote equality and to fight against racism, xenophobia and discrimination - Directorate-General for Justice and Consumers

The Directorate-General for Justice and Consumers, under the citizens, equality, rights and values programme, invites proposals for its call to promote equality and to fight against racism, xenophobia and discrimination. This supports initiatives to prevent and fight against intolerance, racism, xenophobia, and discrimination, in particular on grounds of racial or ethnic origin, colour, religion, sexual orientation or gender identity. Proposals may specifically address the impact of the COVID-19 pandemic on these groups. Projects must fall within one of the following focus areas:

•fighting against intolerance, racism, xenophobia, discrimination, hate speech and hate crimes;

•promoting diversity management and inclusion at the workplace, both in the public and private sector;

•fighting discrimination against LGBTIQ people and promoting LGBTI equality through the implementation of the LGBTIQ equality strategy;

•preventing, reporting and countering hate speech online;

•improving public authority responses to discrimination, racism and xenophobia.

90 % coverage of direct costs and 7 % flat rate for indirect costs

Closing date: 24 February 2022

Further information 


EFSD/Novo Nordisk Foundation future leaders award programme - European Association for the Study of Diabetes

The European Foundation for the Study of Diabetes and the Novo Nordisk Foundation invite applications for their future leaders award programme. This supports clinical and basic scientists in transitioning from postdoctoral clinical fellow to a tenured faculty position in European diabetes research.

Closing date: 1 March 2022

Further information


EFSD/Sanofi outlook to the next 100 years of insulin – innovative insulin delivery and monitoring systems -

European Association for the Study of Diabetes

The European Foundation for the Study of Diabetes and Sanofi invites applications for their outlook to the next 100 years of insulin – innovative insulin delivery and monitoring systems programme. This supports basic and clinical-experimental studies understanding and improving insulin delivery and action.

Non-profit institutions or groups of such institutions from Europe and associated countries are eligible to apply. The PI and any co-investigators must be employed full-time at a non-profit institution and the study must be performed at their place of work.

Grants are worth up to €100,000 each for one year or longer.

Closing date: 1 March 2022

Further information 


CERV-2022-GE — Call for proposals to promote gender equality - Directorate-General for Justice and Consumers

The Directore-General for Justic and Consumers, under its Citizens, Equality, Rights and Values Programme, invites proposals for its call to promote gender equality. This supports the advancement and implementation of policies to promote women’s full enjoyment of rights, freedom from gender stereotypes, gender equality, including work-life balance, women’s empowerment and gender mainstreaming. Projects may fall under the following areas:

•equal participation and representation of women and men in political and economic decision making;

•tackling gender stereotypes, including with a focus on youth, and in advertising and the media.

90 % coverage of direct costs and 7 % flat rate for indirect costs

Closing date: 16 March 2022

Further information 


Support to EFSA in the Safety Assessment of Novel Foods and Nutrient Sources – European Food Safety Authority

ref. GP/EFSA/NUTRI/2021/01

The overall objective of this call is the identification of several partners, among Art. 36 List competent organisations, to which EFSA can entrust at any time during the next 4 years the tasks of contributing to the preparatory work for the safety assessment of novel foods and nutrient sources performed by EFSA. The interested applicants shall cover at least one of the specified 7 areas:

  1. Product characterization
  2. Intake assessment
  3. Absorption, Distribution, Metabolism and Excretion (ADME) & Bioavailability
  4. Nutritional assessment
  5. Toxicological information
  6. Human studies
  7. Allergenicity

This grant is financed based on achievements of results (deliverables) under entrusted task within timeline.

Closing date: 17 February 2022

Further information 

Amerikanska anslag


Federal Funding agencies


Notice of Special Interest (NOSI): The Functional Oral Microbiome: NIH

The National Institute of Dental and Craniofacial Research (NIDCR) is issuing this Notice of Special Interest (NOSI) to encourage research studies that focus beyond the bacteria to the multispecies communities making up the oral microbiome.

To date, most microbiome studies focus on the bacteriome, despite the fact the term "microbiome" refers to all microorganisms. The oral microbiome is comprised of a multitude of organisms, including bacteria, fungi, viruses, archaea and protozoa, which serve an essential role in oral and systemic health. Despite a wealth of knowledge regarding specific species present, much remains unclear regarding the mechanisms driving the stability, persistence, and resistance of the oral community as a whole. Research studies responding to this NOSI must focus on exploring interkingdom microbial interactions or complex community systems and networks in physiologically relevant environments to understand the role of community interactions in the maintenance of health and in driving transition to dysbiosis and disease in the oral cavity. Outcomes from this NOSI are expected to be multi-dimensional and nuanced research that strengthens our understanding of the interconnectedness and uniqueness of the oral microbiome community.

This notice applies to due dates on or after February 5, 2022 and subsequent receipt dates through September 7, 2025.

Further information 


Notice of Special Interest (NOSI): Molecular and Genetic Characterization of Inborn Errors of Immunity: NIH

The purpose of this Notice of Special Interest (NOSI) is to advance the experimental validation and functional characterization of genetic variants in coding or non-coding genomic regions that result in inborn errors of immunity/primary immunodeficiency diseases and to elucidate the molecular, cellular, and immunological mechanisms of these disorders. Understanding the genetic basis of primary immunodeficiency disorders is essential for their diagnosis, prognosis, and the development of precision therapeutics.

This notice applies to due dates on or after February 5, 2022, and subsequent receipt dates through January 7, 2025.

Further information 


Notice of Special Interest (NOSI): RNA Modifications in Cancer Biology: NIH

The purpose of this Notice of Special Interest (NOSI) is to stimulate research on the role of RNA modifications in the area of cancer biology. Despite the recognition that RNA modifications and editing exert substantial impact on gene expression and function, there are a lack of mechanistic insights into the dynamic regulation of RNA modifications and how their de-regulation drives cancer formation. A better understanding of the extent, diversity and crosstalk between different types of RNA modification, and the elucidation of the molecular players that read and interpret the modification code are needed to reveal the mechanisms of RNA modifications that underly cancer formation and the cancer phenotype.

The first available date will be February 16, 2022 to April 22, 2022 pending on various funding opportunity announcements.

Further information 


Drug Discovery For Nervous System Disorders (R01, R21 Clinical Trials Not Allowed): NIH

This Funding Opportunity Announcement (FOA) supports the discovery of novel compounds for the prevention and treatment of nervous system disorders. Through this FOA, NIMH, NIAAA, NIDA and NIA wish to stimulate research in: 1) Identification, design, synthesis, and preclinical testing of small molecules for their potential as candidate therapeutics ; 2) Initial hit-to-lead chemistry to improve activity of compounds against the target of interest; 3) Later stage lead optimization to improve efficacy and pharmacokinetics; and 4) Initial drug metabolism and pharmacokinetic properties (DMPK). Emphasis will be placed on projects that provide novel approaches for identifying potential therapeutic agents.

R21 will also support applications proposing preclinical discovery of biotechnology products and biologics with potential as candidate therapeutics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies).

Deadline: NIH standard due dates.

Funding Opportunity Announcement (FOA): PAR-22-031 (R01); PAR-22-032 (R21).

Further information: (R01); (R21).


Discovery of the Genetic Basis of Childhood Cancers and of Structural Birth Defects: Gabriella Miller Kids First Pediatric Research Program (X01 Clinical Trial Not Allowed): NIH

As part of the Gabriella Miller Kids First Pediatric Research Program (Kids First), the NIH invites applications to submit samples from pediatric cohorts for whole genome sequencing at a Kids First-supported sequencing center. Applicants are encouraged to propose sequencing of existing pediatric cancer cohorts to elucidate the genetic contribution (somatic and/or germline) to childhood cancers, or to expand the range of disorders included within the Kids First Data Resource to investigate the genetic etiology of structural birth defects. The program will accept applications that propose whole genome, exome, and transcriptome sequencing, as well as epigenomic assays of tumor or affected tissue, when justified. These data, and associated clinical and phenotypic data, will become part of the Gabriella Miller Kids First Pediatric Data Resource (Kids First Data Resource) for the pediatric research community.

Deadline: February 23, 2022

Funding Opportunity Announcement (FOA): PAR-22-054

Further information 


Transformative Nucleic Acid Sequencing Technology Innovation and Early Development (R21 Clinical Trial not Allowed): NIH

This Funding Opportunity Announcement (FOA) solicits R21 grant applications to innovate and develop the early stages of novel technologies that will enable greater than a one order of magnitude improvement in 1) DNA sequencing, and 2) methods for direct sequencing of the diversity of entire RNA molecules. Advances in genomics and more broadly in biomedical research have been greatly facilitated by cycles of technology innovation and disruption that have driven significant and sustained nucleic acid sequencing throughput and assembly quality increases combined with cost decreases and read quality improvements. The goal now is to dramatically advance DNA sequencing and direct RNA sequencing technologies at reasonable costs with the anticipation that significant exploratory innovation in any of these and related areas would make significant contributions to the mission of NHGRI and the field of genomics, including to many of NHGRI’s other technology development goals.

Deadline: March 1, 2022; February 1, 2023.

Funding Opportunity Announcement (FOA): RFA-HG-21-007

Further information




Robert B Winter global outreach fellowship- Scoliosis Research Society, US

This 4-6 week spine fellowship is for highly-motivated spine surgeons who are currently in clinical practice in any financially-challenged under-served area worldwide, and who are in a position which will enable them to disseminate knowledge acquired during the fellowship to others in their home country upon their return. The candidate will have the choice to indicate his/her preference for the host site from a provided list of approved centers. It is imperative that the fellow be from a site that has the ability to perform complex spine surgery after completion of the fellowship. The SRS host may also visit the Winter fellow's home site to follow-up on skills and knowledge learned.

  • Four-to-six-week fellowship at a recognized global spine center which is staffed with SRS Active fellows.
  • Financial assistance approximating $12,000 to fund travel and lodging expenses.
  • Final report of the learning experience to be sent to the Scholarship and Awards Committee within two months of finishing the visiting fellowship.

Deadline: Application will open January 1 and close March 1, 2022.

Further information


Global haemophilia ASPIRE research awards, Pfizer, US

Pfizer invites proposals for its ASPIRE haemophilia research awards. These support research in gene therapy for haemophilia. Projects may fall under the following categories:

•basic and clinical science of gene therapy for haemophilia;

•basic and clinical science of TFPI and anti-TFPI monoclonal antibodies;

•burden of disease – clinical haemophilia A and B.

One grant is available for a basic science project, worth up to USD 90,000 per year for one to two years. One grant is available for a clinical science project, worth up to USD 110,000 per year for one to two years. Overhead rates of up to 28% of the total proposed project budget may be supported by Pfizer.

Deadline:  Proposal Deadline:1 March 2022; Anticipated Full Proposal Notification Date: May 2022.

Further information